CUE
Cue BiopharmaNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$103.03M
P/E Ratio
—
EPS
$-4.53
Beta
2.39
52W High
$41.42
52W Low
$4.97
50-Day MA
$21.88
200-Day MA
$16.92
Dividend Yield
—
Profit Margin
-59.70%
Forward P/E
—
PEG Ratio
—
About Cue Biopharma
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biological drugs for the selective modulation of the human immune system to treat a variety of cancers, chronic infectious diseases, and autoimmune disorders. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $32.73M |
| Gross Profit (TTM) | $-2.11M |
| EBITDA | $-18.16M |
| Operating Margin | -94.30% |
| Return on Equity | -138.50% |
| Return on Assets | -46.10% |
| Revenue/Share (TTM) | $8.75 |
| Book Value | $6.64 |
| Price-to-Book | 4.81 |
| Price-to-Sales (TTM) | 3.15 |
| EV/Revenue | 2.781 |
| EV/EBITDA | -1.76 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 1251.00% |
| Shares Outstanding | $4.20M |
| Float | $3.61M |
| % Insiders | 8.55% |
| % Institutions | 17.63% |
Historical Volatility
HV 10-Day
226.93%
HV 20-Day
172.87%
HV 30-Day
142.86%
HV 60-Day
127.04%
HV Rank
88.5%
Volatility is currently expanding
Analyst Ratings
Consensus ($115.00 target)
1
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026